Aurobindo Pharma's unit VII facility gets OAI from US FDA

Aurobindo Pharma announced that the US Food and Drug Administration (FDA) classified the inspection of the company's oral solids formulation manufacturing facility of Unit VII as official action indicated (OAI). "The company believes that this OAI classification will not have any material impact on the existing revenues or the supplies to our US business at this juncture," Aurobindo Pharma said in a BSE filing. The company will work closely with the regulator to comprehensively address the issues

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.000886 seconds